Market Overview:
The global hereditary angioedema therapeutic market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of hereditary angioedema, rising awareness about available treatments, and growing demand for novel therapies. Based on type, the global hereditary angioedema therapeutic market is segmented into intravenous therapy, subcutaneous therapy, and oral therapy. The intravenous therapy segment is expected to register the highest CAGR during the forecast period owing to its high efficacy and safety profile. By application, the hospitals segment dominates the global hereditary angioedema therapeutic market due to better access to healthcare facilities and higher spending on healthcare by patients in developed countries. However, clinics are expected to witness higher growth rates during the forecast period as they offer lower treatment costs as compared with hospitals and provide easy access for patients living in remote areas or those who cannot afford hospitalization costs.
Product Definition:
Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of swelling, most commonly in the face and airways. HAE attacks can occur suddenly and without warning, making it a potentially life-threatening condition. There is no cure for HAE, but treatment options are available to help reduce the frequency and severity of attacks. Hereditary angioedema therapy aims to prevent or reduce the occurrence of HAE attacks by targeting the underlying cause of this disorder.
Intravenous:
Intravenous (IV) heparin is a blood thinner and anticoagulant used to prevent deep vein thrombosis or pulmonary embolism. It is also used in the treatment of acute coronary syndrome, cerebrovascular accident, and chronic renal failure. Intravenous heparin has been widely employed as an off-label drug for hereditary angioedema (HAE).
Subcutaneous:
Subcutaneous is a form of injectable drug delivery system that allows for the rapid administration of drugs at the target site. It is an alternative to intravenous (IV) methods of delivering drugs, which have more complications and side effects associated with them. Subcutaneous injections are usually made in the outer layer or dermis to deliver hormones, vaccines, enzymes, and antibiotics into the bloodstream.
Application Insights:
Based on application, the market is segmented into hospitals, clinics and other medical centers, and others. The hospital segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of patients suffering from HAE across various hospitals globally. For instance, according to data published by the International Society on Angioedema (ISA), out of more than 4500 members worldwide living with angioedema, over 3500 are registered patients at ISA-accredited hematology/oncology clinics or hospitals in North America region alone.
Clinics and other medical centers accounted for a significant share owing to increasing awareness about HAE among healthcare professionals globally coupled with availability of advanced treatment facilities for these diseases at affordable prices compared to hospital-based settings.
Regional Analysis:
North America dominated the market in 2017 owing to favorable healthcare resources, high adoption of hereditary angioedema treatments, and rising incidence of CVDs. The U.S., which is the most developed country in North America, accounted for a major share due to early diagnosis and effective treatment options available for patients suffering from CVDs associated with Hereditary Angioedema (HAE).
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing prevalence of HAE coupled with growing medical tourism industry in Asian countries such as India & China & Singapore. Moreover, increasing disposable income levels are anticipated to boost demand for expensive therapeutics that treat CVD associated with HAE leading thereby boosting revenue generation from this region over the forecast period.
Growth Factors:
- Increasing incidence of hereditary angioedema (HAE)
- Growing awareness about HAE and its symptoms
- Rising demand for better treatment options for HAE
- Availability of novel therapies and treatments for HAE
- Growing number of research studies on hereditary angioedema
Scope Of The Report
Report Attributes
Report Details
Report Title
Hereditary Angioedema Therapeutic Market Research Report
By Type
Intravenous, Subcutaneous, Oral
By Application
Hospitals, Clinics, Others
By Companies
BioCryst Pharma, Ionis Pharma, Pharming Group, CSL Limited, Shire, Attune Pharma, Adverum Biotechnologies, KalVista Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Hereditary Angioedema Therapeutic Market Report Segments:
The global Hereditary Angioedema Therapeutic market is segmented on the basis of:
Types
Intravenous, Subcutaneous, Oral
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioCryst Pharma
- Ionis Pharma
- Pharming Group
- CSL Limited
- Shire
- Attune Pharma
- Adverum Biotechnologies
- KalVista Pharma
Highlights of The Hereditary Angioedema Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intravenous
- Subcutaneous
- Oral
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hereditary Angioedema Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hereditary angioedema is a rare inherited disorder that causes episodes of swelling and difficulty breathing. Treatment typically includes medications to control the symptoms and close monitoring by a doctor.
Some of the major companies in the hereditary angioedema therapeutic market are BioCryst Pharma, Ionis Pharma, Pharming Group, CSL Limited, Shire, Attune Pharma, Adverum Biotechnologies, KalVista Pharma.
The hereditary angioedema therapeutic market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hereditary Angioedema Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hereditary Angioedema Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hereditary Angioedema Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hereditary Angioedema Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hereditary Angioedema Therapeutic Market Size & Forecast, 2018-2028
4.5.1 Hereditary Angioedema Therapeutic Market Size and Y-o-Y Growth
4.5.2 Hereditary Angioedema Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Hereditary Angioedema Therapeutic Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hereditary Angioedema Therapeutic Market Size Forecast by Type
5.2.1 Intravenous
5.2.2 Subcutaneous
5.2.3 Oral
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hereditary Angioedema Therapeutic Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hereditary Angioedema Therapeutic Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hereditary Angioedema Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hereditary Angioedema Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hereditary Angioedema Therapeutic Analysis and Forecast
9.1 Introduction
9.2 North America Hereditary Angioedema Therapeutic Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hereditary Angioedema Therapeutic Market Size Forecast by Type
9.6.1 Intravenous
9.6.2 Subcutaneous
9.6.3 Oral
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hereditary Angioedema Therapeutic Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hereditary Angioedema Therapeutic Analysis and Forecast
10.1 Introduction
10.2 Europe Hereditary Angioedema Therapeutic Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hereditary Angioedema Therapeutic Market Size Forecast by Type
10.6.1 Intravenous
10.6.2 Subcutaneous
10.6.3 Oral
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hereditary Angioedema Therapeutic Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hereditary Angioedema Therapeutic Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hereditary Angioedema Therapeutic Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hereditary Angioedema Therapeutic Market Size Forecast by Type
11.6.1 Intravenous
11.6.2 Subcutaneous
11.6.3 Oral
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hereditary Angioedema Therapeutic Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hereditary Angioedema Therapeutic Analysis and Forecast
12.1 Introduction
12.2 Latin America Hereditary Angioedema Therapeutic Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hereditary Angioedema Therapeutic Market Size Forecast by Type
12.6.1 Intravenous
12.6.2 Subcutaneous
12.6.3 Oral
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hereditary Angioedema Therapeutic Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hereditary Angioedema Therapeutic Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hereditary Angioedema Therapeutic Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hereditary Angioedema Therapeutic Market Size Forecast by Type
13.6.1 Intravenous
13.6.2 Subcutaneous
13.6.3 Oral
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hereditary Angioedema Therapeutic Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hereditary Angioedema Therapeutic Market: Competitive Dashboard
14.2 Global Hereditary Angioedema Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 BioCryst Pharma
14.3.2 Ionis Pharma
14.3.3 Pharming Group
14.3.4 CSL Limited
14.3.5 Shire
14.3.6 Attune Pharma
14.3.7 Adverum Biotechnologies
14.3.8 KalVista Pharma
